Health wearable devices effectively promote bodyweight in overweight/obese individuals
1. Use of accelerometer/pedometer-only and commercial health wearable-only were the most effective at reducing body weight in comparison with the ...
Tag: overweight
Once weekly tirzepatide is superior to daily insulin degludec for treatment of uncontrolled type 2 diabetes
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec ...
Association between BMI and diabetes risk among low-middle income countries varies considerably by geographical region
1. Standard BMI thresholds associated with greater risk of diabetes varied across 57 low- and middle-income countries depending on geographical ...
Increasing obesity and BMI trends have slowed in the past decade among the general Chinese adult population
1. Mean BMI and obesity prevalence increased more rapidly between 2004-2010 than between 2010-2018. 2. Divergent trends were seen between ...
Metabolic–bariatric surgery associated with reduced all-cause mortality compared to non-surgical management of obesity
1. Matched cohort meta-analysis showed significant morality and life expectancy benefits with metabolic–bariatric surgery compared to non-surgical management of obesity. ...
Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
#VisualAbstract: Semaglutide 2.4 mg once a week decreases bodyweight in overweight or obese patients with type 2 diabetes
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients on ...
Semaglutide 2.4 mg once a week decreases bodyweight in overweight or obese patients with type 2 diabetes
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients ...
Weekly semaglutide effective for decreasing body weight in obesity
1. Once-weekly treatment of semaglutide was associated with meaningful body weight reduction at 68 weeks compared to placebo in patients ...
Thirty minutes of moderate physical activity associated with significantly improved outcomes for patients with obesity and metabolic syndrome
1. For older adults with overweight or obesity, and metabolic syndrome, replacing 30 minutes of inactive time with moderate to ...